Published in Vaccine Weekly, November 7th, 2001
The randomized, double-blind, placebo-controlled study will be conducted in the United States in 120 symptomatic asthma patients who are not being treated with controller medications including inhaled steroids, leukotriene modifiers, or long-acting beta agonists. Following a run-in period of two weeks' duration to confirm disease activity, patients will be randomized to one of two dosing regimens of humanized anti-IL-4 antibody or placebo. Patients will receive three, monthly intravenous infusions with a four-month...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly